These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 3481041)
1. Methodology for the rational development of methotrexate analogs in the clinic. Leyland-Jones B; O'Dwyer PJ; Hoth DF; Wittes RE NCI Monogr; 1987; (5):93-7. PubMed ID: 3481041 [TBL] [Abstract][Full Text] [Related]
2. Trimetrexate: clinical development of a nonclassical antifolate. O'Dwyer PJ; DeLap RJ; King SA; Grillo-Lopez AJ; Hoth DF; Leyland-Jones B NCI Monogr; 1987; (5):105-9. PubMed ID: 2963228 [TBL] [Abstract][Full Text] [Related]
3. Antifolate analogs: mechanism of action, analytical methodology, and clinical efficacy. Fleisher M Ther Drug Monit; 1993 Dec; 15(6):521-6. PubMed ID: 8122287 [TBL] [Abstract][Full Text] [Related]
4. Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. Lathan B; Von Hoff DD; Elslager E Cancer Treat Rep; 1984 May; 68(5):733-8. PubMed ID: 6233003 [TBL] [Abstract][Full Text] [Related]
5. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate. Senkovich O; Schormann N; Chattopadhyay D Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691 [TBL] [Abstract][Full Text] [Related]
6. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863 [TBL] [Abstract][Full Text] [Related]
7. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Diddens H; Niethammer D; Jackson RC Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514 [TBL] [Abstract][Full Text] [Related]
8. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells. Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987 [TBL] [Abstract][Full Text] [Related]
9. Folate and antifolate pharmacology. Kamen B Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Elliott WL; Roberts BJ; Howard CT; Leopold WR Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790 [TBL] [Abstract][Full Text] [Related]
11. [Secondary microbial metabolites with potentials for antineoplastic actions: antineoplastic antibiotics and immunopotentiators]. Umezawa H Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1071-86. PubMed ID: 6191672 [TBL] [Abstract][Full Text] [Related]
13. Approaches to selectivity in cancer chemotherapy. Bertino JR Adv Pathobiol; 1976; 2():65-9. PubMed ID: 1088246 [TBL] [Abstract][Full Text] [Related]
14. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Schmid FA; Sirotnak FM; Otter GM; DeGraw JI Cancer Treat Rep; 1985 May; 69(5):551-3. PubMed ID: 4005878 [TBL] [Abstract][Full Text] [Related]
15. Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate. Pineda P; Kanter A; McIvor RS; Benkovic SJ; Rosowsky A; Wagner CR J Med Chem; 2003 Jul; 46(14):2816-8. PubMed ID: 12825924 [TBL] [Abstract][Full Text] [Related]
16. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats. Han YH; Kato Y; Watanabe Y; Terao K; Asoh Y; Sugiyama Y Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):394-400. PubMed ID: 11259322 [TBL] [Abstract][Full Text] [Related]
17. Trimetrexate: review and current clinical experience in advanced colorectal cancer. Blanke CD; Messenger M; Taplin SC Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022 [TBL] [Abstract][Full Text] [Related]
18. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. Jolivet J; Chabner BA J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143 [TBL] [Abstract][Full Text] [Related]
19. Future clinical investigations with anthracycline antibiotics in relation to daunorubicin. Muggia FM; Blum RH; Wernz JC Cancer Treat Rep; 1981; 65 Suppl 4():35-7. PubMed ID: 6955012 [TBL] [Abstract][Full Text] [Related]
20. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Whittle SL; Hughes RA Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]